查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球临床试验市场 - 2023-2030
市场调查报告书
商品编码
1279674

全球临床试验市场 - 2023-2030

Global Clinical Trials Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

全球临床试验市场预计将实现利润丰厚的增长，到 2022 年将达到 566.407 亿美元，到 2030 年将达到 992.12 亿美元。 在预测期内（2023-2030 年），临床试验市场预计将以 7.4% 的复合年增长率增长。

临床试验是一种临床调查程序，由经过仔细验证的指定协议监督，以解决详细的患者护理查询。 临床试验分为五个阶段，每个阶段都有特定的临床试验目的。 所有临床试验均受制于定义谁可以参与试验的系统。 研发支出的增加、对新疗法的需求不断增加以及不断变化的监管指南正在推动预测期内全球临床试验市场的增长。

市场动态

合同研究组织 (CROS) 的兴起预计将在预测期内推动临床试验市场的增长

每年，製药行业都会生产各种具有显着医疗效益的新药。 药物发现是一个昂贵且不确定的过程，许多潜在的药物从未进入市场。 因此，公司将这些任务外包给 CRO 以降低成本。 CRO 为製药和生物技术公司提供药物研究外包服务。

CRO 根据所有标准和法规要求管理和完成图像处理过程，以实现顺利的图像采集、分析、註释和传输。 近年来，CRO 服务在开发新药和治疗的早期阶段协助公司。 製药公司越来越多地使用临床研究、咨询和实验室 CRO 服务。

临床研究资金的增加正在推动全球临床试验市场的增长

未来几年，预计来自各个主管部门的资金增加将为全球临床试验市场提供有利可图的增长机会。 例如，2023年1月，作为加拿大生物製造和生命科学战略（BLSS）的一部分，加拿大卫生研究院（CIHR）的临床试验基金（CTF）启动了中风研究、行为改变、生物统计学和临床研究。我们计划接受超过 3200 万加元的共同投资，以向新一代研究人员和研究人员传授我们的专业知识，包括我们已知的方法。

COVID-19 影响分析

对 COVID-19 的分析包括 COVID 之前、COVID 和 COVID 之后的情景、价格动态（与 COVID 之前的情景相比，大流行期间和之后的价格变动）、供需范围（由于供应和需求的变化还解释了贸易限制、封锁和后续问题）、政府举措（政府机构为振兴市场、部门和行业而采取的举措）、製造商的战略举措（製造商为缓解 COVID 问题所做的努力）。

俄乌战争影响分析

乌克兰和俄罗斯都是国际临床试验活动的广泛基地。 对乌克兰的攻击可能会破坏国际临床试验的结果，因为这两个国家有前途的招募中心都失败了。 军事衝突造成的中断对医疗保健产生了重大影响，包括临床试验和癌症护理。

全球经济衰退影响分析

一些专家担心，随着经济持续放缓，许多国家正处于衰退的边缘。 公司正在密切关注其影响，但生物製药领域尤为关注。 经济衰退将不可避免地迫使一些公司改变他们的方法。 但一些生物技术公司可能会受到更健康的结果的影响。 预计生物技术公司将寻求技术来填补资金缺口，从而提高效率、更快获得结果并改变生物技术研究人员的工作方式。

人工智能影响分析

人工智能对临床试验市场产生积极影响。 通过采用 AI 支持的技术，研究人员可以从过去和最近的研究中获得见解，探索大量数据，并报告对未来研究设计的任何必要调整。 在进一步的临床试验中，人工智能在诊断和治疗疾病方面也有很大的应用潜力。

内容

第一章调查方法及范围

  • 调查方法
  • 调查目的和范围

第 2 章定义和概述

第 3 章执行摘要

  • 特定阶段的片段
  • 设计的片段
  • 按视图摘录
  • 按服务分类的片段
  • 区域摘要

第四章市场动态

  • 影响因素
    • 主持人
      • 研发费用增加
      • 有利的监管准则
    • 约束因素
      • 成本高，成功概率低
    • 机会
    • 政府举措
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 害虫分析
  • 监管分析
  • 价格分析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • COVID-19 之前的情景
    • 当前的 COVID-19 情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格和动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 结论

第七章俄乌战争分析

第八章全球经济衰退分析

第9章人工智能的影响分析

第 10 章阶段

  • 第三阶段
  • 第二阶段
  • 第一阶段
  • 第四阶段

第 11 章的设计

  • 治疗研究
    • 随机对照试验
      • 双盲随机研究
      • 单盲随机研究
      • 非盲随机试验
    • 适应性临床试验
    • 非随机对照试验
  • 观察研究
    • 潜在队列
      • 回顾性队列
      • 时间序列队列
    • 病例对照研究
    • 队列研究
    • 横断面研究
    • 生态研究

第12章适应症

  • 肿瘤科
  • 免疫疾病
  • 糖尿病
  • 感染
  • 其他

第 13 章服务

  • 实验室服务
  • 医疗器械测试服务
  • 临床试验数据管理服务
  • 生物分析测试服务
  • 其他

第14章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第15章竞争格局

  • 竞争场景
  • 市场份额分析
  • 併购分析

第十六章公司简介

  • Iqvia Holdings Inc.（Q2 解决方案）
    • 公司简介
    • 阶段组合和描述
    • 财务摘要
    • 主要发展状况
  • Parexel International Corporation
  • Charles River Laboratories International, Inc.
  • Syneos Health, Inc.
  • WuXi AppTec Co., Ltd.（WuXi Clinical）
  • ICON plc
  • Thermo Fisher Scientific（Pharmaceutical Product Development LLC）
  • Azelix
  • Pharmaron Beijing Co., Ltd.
  • Celerion

第17章 附录

简介目录
Product Code: PH244

Market Overview

The global clinical trials market reached USD 56,640.7 million in 2022 and is projected to witness lucrative growth by reaching up to USD 99,212.0 million by 2030. The clinical trials market is expected to exhibit a CAGR of 7.4% during the forecast period (2023-2030).

Clinical trials are a methodology of clinical investigation that is overseen by a designated protocol that is carefully verified to respond to a detailed patient care query. Clinical trials are bifurcated into five phases, with every phase carrying a specific intent within the clinical trial. Every trial confers to a system that defines what sorts of people may partake in the study. The increasing R&D spending, growing need for new therapeutics, and evolving regulatory guidelines are driving the global clinical trials market growth during the forecast period.

Market Dynamics

The Rising Number of Contract Research Organizations (CROS) is Expected to Drive the Clinical Trials Market Growth During the Forecast Period.

Every year, the pharmaceutical industry creates a variety of new drugs that provide significant medical advantages. Developing new medicines is a costly and uncertain process, and many potential drugs never make it to market as a result, in order to save money, companies outsource these tasks to CROs. CROs provide pharmaceutical and biotechnology industries with outsourced pharmaceutical research services.

The CROs manage and complete the imaging process in accordance with all standards and regulatory requirements, ensuring smooth image acquisition, analysis, annotation, and transfer. In recent years, CRO services have helped companies in the early stages of developing novel medicines and therapies. Pharmaceutical firms are increasingly using clinical research, consultancy, and laboratory CRO services.

The Increasing Funding for Clinical Research is Driving the Global Clinical Trials Market Growth.

The growing funding from various authorities is expected to provide the global clinical trials market with lucrative growth opportunities in the upcoming years. For instance, in January 2023, as part of Canada's Biomanufacturing and Life Sciences Strategy (BLSS), the Canadian Institutes of Health Research (CIHR) Clinical Trials Fund (CTF) is expected to be accepting a joint investment of more than CAD 32 M to instruct a fresh generation of researchers and investigators in expertise as stroke research, behavioral change, biostatistics, and the known approach of clinical research.

COVID-19 Impact Analysis

The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario along with pricing dynamics (including pricing change during and post-pandemic comparing it to pre-COVID scenarios), demand-supply spectrum (shift in demand and supply owing to trading restrictions, lockdown, and subsequent issues), government initiatives (initiatives to revive market, sector or industry by government bodies) and manufacturers strategic initiatives (what manufacturers did to mitigate the COVID issues will be covered here).

Russia-Ukraine War Impact Analysis

Ukraine and Russia are both extensive bases for international clinical trial activity. The attack on Ukraine may cause an underpowering of global clinical trial outcomes with the failure of prospective recruitment locations for both nations. The turmoil and disorder induced by military confrontation have a significant influence over healthcare including clinical trials and cancer care.

Global Recession Impact Analysis

As the economic slump persists, multiple specialists are concerned that many countries are on the cusp of a recession. While every enterprise is overseeing the possible fallout, those in the biopharma domain may be especially anxious regarding the outcomes. The recession is expected inevitably cause multiple firms to alter their approach. Nonetheless, it could influence a few biotechs for sounder outcomes. It is anticipated that biotechs' will look towards technology to compensate for funding shortcuts, that are expected to result in improved efficiencies, quicker results, and a shift in the way biotech researchers work.

Artificial Intelligence Impact Analysis

Artificial intelligence has a positive impact on the clinical trials market as employing AI-enabled technologies, the investigators can analyze and yield understanding from prior and recent trials, research huge data, and report the needed adjustment in prospective trial designs. In further clinical trials, AI has a tremendous possibility in the diagnosis of disorders and treatment applications as well.

Segment Analysis

The global clinical trials market is segmented based on phase, design, indication, service, and region.

The Phase III Segment is Estimated to Hold a 47.6% Share of the Global Market by 2030.

The phase III segment is estimated to hold about 47.1% of the global clinical trials market by 2030. For instance, in May 2022, the last patient is projected to begin treatment in June 2022, according to Lipidor AB (publ), which reports that half of the patients have already been enrolled in the Phase III research of the AKP02 skin spray for mild to moderate psoriasis. In the third quarter of 2022, top-line results from the Phase III investigation are anticipated.

In December 2022, by showing a statistically significant decrease in HbA1c (a measure of average blood sugar) with Jardiance (empagliflozin) compared with placebo for children and adolescents aged 10-17 years with type 2 diabetes, the DINAMO phase III clinical trial fulfilled its primary aim.

Geographical Analysis

Europe is Estimated to Hold the Second-largest Share of the Global Clinical Trials Market During the Forecast Period.

The increasing government initiatives for research drive the market in the European region and are estimated to hold around 27.7% of the total global market by 2030. For instance, in January 2022, the European Commission (EC), the Heads of Medicines Agencies, and the European Medicines Agency introduced an initiative to transform how clinical trials are initiated, developed, and run, directed to Accelerating Clinical Trials in the EU (ACT EU).

The goal is to further expand the EU as a focal point for clinical research, advance the development of high-quality, safe, and effective medicines, and better incorporate clinical research in the European health system. Creating the application of the Clinical Trials Regulation and the takeoff of the Clinical Trials Information Systems in January 2022, ACT EU will support the European environment for clinical trials while maintaining data robustness, a high level of protection of trial participants, and the transparency that EU citizens expect.

Competitive Landscape

The major global players in the market include: Iqvia Holdings Inc. (Q2 Solutions), Parexel International Corporation, Charles River Laboratories International, Inc., Syneos Health, Inc., WuXi AppTec Co., Ltd. (WuXi Clinical), ICON plc, Thermo Fisher Scientific (Pharmaceutical Product Development LLC), Azelix, Pharmaron Beijing Co., Ltd., and Celerion among others.

Why Purchase the Report?

  • To visualize the global clinical trials market segmentation based on product, application, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of clinical trials market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global clinical trials market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Phase
  • 3.2. Snippet by Design
  • 3.3. Snippet by Indication
  • 3.4. Snippet by Service
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing R&D Spending.
      • 4.1.1.2. Favorable Regulatory Guidelines.
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost and Low Success Probability.
    • 4.1.3. Opportunity
    • 4.1.4. Government Initiatives
    • 4.1.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. PEST Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Global Recession Analysis

9. Artificial Intelligence Impact Analysis

10. By Phase

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phase
    • 10.1.2. Market Attractiveness Index, By Phase
  • 10.2. Phase III
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Phase II
  • 10.4. Phase I
  • 10.5. Phase IV

11. By Design

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
    • 11.1.2. Market Attractiveness Index, By Design
  • 11.2. Treatment Studies*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 11.2.3. Randomized Control Trial
      • 11.2.3.1. Double-Blind Randomized Trial
      • 11.2.3.2. Single Blind Randomized Trial
      • 11.2.3.3. Non-Blind Randomized Trial
    • 11.2.4. Adaptive Clinical Trial
    • 11.2.5. Non-Randomized Control Trial
  • 11.3. Observational Studies
    • 11.3.1. Prospective Cohort
      • 11.3.1.1. Retrospective Cohort
      • 11.3.1.2. Time Series Cohort
    • 11.3.2. Case-Control Study
    • 11.3.3. Cohort Study
    • 11.3.4. Cross-Sectional Study
    • 11.3.5. Ecological Study

12. By Indication

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 12.1.2. Market Attractiveness Index, By Indication
  • 12.2. Oncology
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Immunological Diseases
  • 12.4. Diabetes
  • 12.5. Infectious diseases
  • 12.6. Others

13. By Services

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Services
    • 13.1.2. Market Attractiveness Index, By Services
  • 13.2. Laboratory Services
    • 13.2.1. Introduction
    • 13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 13.3. Medical Device Testing Services
  • 13.4. Clinical Trial Data Management Services
  • 13.5. Bioanalytical Testing Services
  • 13.6. Others

14. By Region

  • 14.1. Introduction
    • 14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 14.1.2. Market Attractiveness Index, By Region
  • 14.2. North America
    • 14.2.1. Introduction
    • 14.2.2. Key Region-Specific Dynamics
    • 14.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phase
    • 14.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
    • 14.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 14.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Services
    • 14.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.2.7.1. The U.S.
      • 14.2.7.2. Canada
      • 14.2.7.3. Mexico
  • 14.3. Europe
    • 14.3.1. Introduction
    • 14.3.2. Key Region-Specific Dynamics
    • 14.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phase
    • 14.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
    • 14.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 14.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Services
    • 14.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.3.7.1. Germany
      • 14.3.7.2. The U.K.
      • 14.3.7.3. France
      • 14.3.7.4. Italy
      • 14.3.7.5. Spain
      • 14.3.7.6. Rest of Europe
  • 14.4. South America
    • 14.4.1. Introduction
    • 14.4.2. Key Region-Specific Dynamics
    • 14.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phase
    • 14.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
    • 14.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 14.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Services
    • 14.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.4.7.1. Brazil
      • 14.4.7.2. Argentina
      • 14.4.7.3. Rest of South America
  • 14.5. Asia-Pacific
    • 14.5.1. Introduction
    • 14.5.2. Key Region-Specific Dynamics
    • 14.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phase
    • 14.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
    • 14.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 14.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Services
    • 14.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.5.7.1. China
      • 14.5.7.2. India
      • 14.5.7.3. Japan
      • 14.5.7.4. Australia
      • 14.5.7.5. Rest of Asia-Pacific
  • 14.6. Middle East and Africa
    • 14.6.1. Introduction
    • 14.6.2. Key Region-Specific Dynamics
    • 14.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phase
    • 14.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
    • 14.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 14.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Services

15. Competitive Landscape

  • 15.1. Competitive Scenario
  • 15.2. Market Share Analysis
  • 15.3. Mergers and Acquisitions Analysis

16. Company Profiles

  • 16.1. Iqvia Holdings Inc. (Q2 Solutions)
    • 16.1.1. Company Overview
    • 16.1.2. Phase Portfolio and Description
    • 16.1.3. Financial Overview
    • 16.1.4. Key Developments
  • 16.2. Parexel International Corporation
  • 16.3. Charles River Laboratories International, Inc.
  • 16.4. Syneos Health, Inc.
  • 16.5. WuXi AppTec Co., Ltd. (WuXi Clinical)
  • 16.6. ICON plc
  • 16.7. Thermo Fisher Scientific (Pharmaceutical Product Development LLC)
  • 16.8. Azelix
  • 16.9. Pharmaron Beijing Co., Ltd.
  • 16.10. Celerion

LIST NOT EXHAUSTIVE

17. Appendix

  • 17.1. About Us and Services
  • 17.2. Contact Us